Gonzalo V. Gonzalez-Stawinski
Research Subjects
Gonzalo V. Gonzalez-Stawinski has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Nicholas G. Smedira
Department of Thoracic and Cardiovascular Surgery, The Cleveland Clinic Foundation, Cleveland, OH
4 shared publicationsRandall C. Starling
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH
3 shared publications- Shelley A. Hall
Baylor University Medical Center, Dallas, Texas, USA
3 shared publications Aayla K. Jamil
Annette C. and Harold C. Simmons Transplant Institute, Baylor Scott & White Research InstituteDallasTexas
2 shared publicationsAlbert S.Y. Chang
2 shared publications- Brian Lima
Department of Cardiac Surgery, Vanderbilt University Medical Center, Nashville, Tennessee
2 shared publications
Latest Publications
- 28 March 2019
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 32 (2) , 177-180
Outcomes of orthotopic heart transplantation and left ventricular assist device in patients aged 65 years or more with end-stage heart failure
Age has traditionally been a limiting factor for advanced heart failure (HF) therapies. Orthotopic heart transplantation (OHT) age guidelines have become less restrictive, and left ventricular assist devices (LVADs) are increasingly utilized as destination therapy for patients ≥65 years. Although indications differ, we assessed outcomes for both modalities in this older population. We reviewed charts of consecutive advanced HF therapy recipients aged ≥65 years at our center from 2012 to 2016. Of 118 patients evaluated, 46 (39%) received an LVAD and 72 (61%) received OHT. Gender, body mass index, and rate of prior sternotomy were similar between groups; OHT recipients were younger, less likely to have diabetes mellitus, and more likely to have HF due to ischemic etiology. Forty-six percent of patients receiving LVADs were urgent need (Interagency Registry for Mechanically Assisted Circulatory Support [INTERMACS] profile 1–2), compared to 29% of patients receiving OHT (United Network for Organ Sharing 1A criteria; P = 0.068). OHT recipients had shorter lengths of stay and better 1-year survival compared to LVAD recipients. Although many centers do not offer advanced HF therapy to patients aged ≥65 years, our results indicate that age alone should not be prohibitive for advanced HF therapy, particularly OHT.
- 28 March 2019
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 32 (2) , 177-180
Outcomes of orthotopic heart transplantation and left ventricular assist device in patients aged 65 years or more with end-stage heart failure
Age has traditionally been a limiting factor for advanced heart failure (HF) therapies. Orthotopic heart transplantation (OHT) age guidelines have become less restrictive, and left ventricular assist devices (LVADs) are increasingly utilized as destination therapy for patients ≥65 years. Although indications differ, we assessed outcomes for both modalities in this older population. We reviewed charts of consecutive advanced HF therapy recipients aged ≥65 years at our center from 2012 to 2016. Of 118 patients evaluated, 46 (39%) received an LVAD and 72 (61%) received OHT. Gender, body mass index, and rate of prior sternotomy were similar between groups; OHT recipients were younger, less likely to have diabetes mellitus, and more likely to have HF due to ischemic etiology. Forty-six percent of patients receiving LVADs were urgent need (Interagency Registry for Mechanically Assisted Circulatory Support [INTERMACS] profile 1–2), compared to 29% of patients receiving OHT (United Network for Organ Sharing 1A criteria; P = 0.068). OHT recipients had shorter lengths of stay and better 1-year survival compared to LVAD recipients. Although many centers do not offer advanced HF therapy to patients aged ≥65 years, our results indicate that age alone should not be prohibitive for advanced HF therapy, particularly OHT.
- 28 September 2018
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 31 (4) , 482-486
Salvage of severe primary graft dysfunction following heart transplantation using extracorporeal life support
Primary graft dysfunction (PGD) is the leading cause of early mortality after heart transplantation. Typically, mechanical circulatory support is necessary to provide hemodynamic support and to enable graft recovery. However, both the reported incidence of PGD and the reported salvage rates with extracorporeal membrane oxygenation (ECMO) vary widely. This may partly be due to variations in the definition of PGD and its levels of severity. We analyzed a prospectively maintained database of 255 transplant recipients at our institution to determine the effectiveness of ECMO support in those who develop severe PGD as defined by the International Society for Heart and Lung Transplantation consensus guidelines. Nineteen (7.5%) patients (aged 32–69 years) developed severe PGD and were treated with veno-arterial (VA) ECMO, which was initiated in the operating room at the time of transplant in most patients. The majority received VA ECMO through femoral cannulation. Two patients required veno-venous ECMO for respiratory support after VA ECMO separation. The 30-day in-hospital survival rate following transplantation was 63% (n = 12). In conclusion, ECMO proved to be a viable option for early hemodynamic support in patients with severe PGD and has become our preferred modality for mechanical circulatory support in these patients.
- 28 September 2018
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 31 (4) , 482-486
Salvage of severe primary graft dysfunction following heart transplantation using extracorporeal life support
Primary graft dysfunction (PGD) is the leading cause of early mortality after heart transplantation. Typically, mechanical circulatory support is necessary to provide hemodynamic support and to enable graft recovery. However, both the reported incidence of PGD and the reported salvage rates with extracorporeal membrane oxygenation (ECMO) vary widely. This may partly be due to variations in the definition of PGD and its levels of severity. We analyzed a prospectively maintained database of 255 transplant recipients at our institution to determine the effectiveness of ECMO support in those who develop severe PGD as defined by the International Society for Heart and Lung Transplantation consensus guidelines. Nineteen (7.5%) patients (aged 32–69 years) developed severe PGD and were treated with veno-arterial (VA) ECMO, which was initiated in the operating room at the time of transplant in most patients. The majority received VA ECMO through femoral cannulation. Two patients required veno-venous ECMO for respiratory support after VA ECMO separation. The 30-day in-hospital survival rate following transplantation was 63% (n = 12). In conclusion, ECMO proved to be a viable option for early hemodynamic support in patients with severe PGD and has become our preferred modality for mechanical circulatory support in these patients.
- Open Access
- 1 October 2017
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 23 (10) , 765-767
Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse
- 1 October 2017
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 23 (10) , 765-767
Open AccessRational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse
- 1 April 2016
- Published by Elsevier in The American Journal of Cardiology
- Vol. 117 (8) , 1375-1380
Frequency of Massive Cardiac Adiposity (Floating Heart) in the Native Hearts of Patients Having Heart Transplantation at a Single Texas Hospital (2013 to 2015) and Comparison of Various Clinical and Morphologic Variables in the Patients With Massive Versus Nonmassive Cardiac Adiposity
- 1 April 2016
- Published by Elsevier in The American Journal of Cardiology
- Vol. 117 (8) , 1375-1380
Frequency of Massive Cardiac Adiposity (Floating Heart) in the Native Hearts of Patients Having Heart Transplantation at a Single Texas Hospital (2013 to 2015) and Comparison of Various Clinical and Morphologic Variables in the Patients With Massive Versus Nonmassive Cardiac Adiposity
- Open Access
- 16 April 2012
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 27 (3) , 397-399
Inflow Graft Interruption as a Simple Method for Left Ventricular Assist Device Removal After Successful Bridge to Recovery
In this report we provide another method of ventricular assist device separation by simply transecting the inflow graft of a Heart Mate II LVAD without the need of dissecting the left ventricular apex for cases of myocardial recovery. (J Card Surg 2012;27:397‐399)
- 16 April 2012
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 27 (3) , 397-399
Open AccessInflow Graft Interruption as a Simple Method for Left Ventricular Assist Device Removal After Successful Bridge to Recovery
In this report we provide another method of ventricular assist device separation by simply transecting the inflow graft of a Heart Mate II LVAD without the need of dissecting the left ventricular apex for cases of myocardial recovery. (J Card Surg 2012;27:397‐399)
- 6 April 2012
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 31 (6) , 672-673
Fate of retained right ventricular assist device outflow grafts after right ventricular recovery
- 6 April 2012
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 31 (6) , 672-673
Fate of retained right ventricular assist device outflow grafts after right ventricular recovery
- 28 February 2012
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 27 (2) , 246-252
Have Changes in ECMO Technology Impacted Outcomes in Adult Patients Developing Postcardiotomy Cardiogenic Shock?
Extracorporeal membrane oxygenation (ECMO) technology has undergone several advancements over the last decade. We sought to compare current ECMO technology to older ones to determine how these technological improvements have impacted outcomes in patients suffering from postcardiotomy cardiogenic shock (PCS). Between 2005 and 2010, 49 patients received ECMO as support for PCS following elective cardiac surgery. Patients were divided into three groups. Group 1 (Gp 1, n = 11) patients received a Biomedicus pump with an Affinity oxygenator, Group 2 (Gp 2, n = 11) patients received a Biomedicus pump with a Quadrox D oxygenator, and Group 3 (Gp 3, n = 27) patients received a Rotaflow pump with a Quadrox D oxygenator. Groups were compared with regards to adverse events and ability to wean. Adverse event analysis showed no statistically significant difference between groups in incidence of stroke (p = 0.08), renal failure (p = 0.88), or bleeding requiring reexploration (p = 0.10). Changes in technology did little to improve weaning rates from ECMO (Gp 1 = 63.6%, Gp 2 = 45.5%, and Gp 3 = 55.6%). Similar trends were detected in hospital survival (Gp 1 = 27.3%, Gp 2 = 27.3%, and Gp 3 = 33.3%). Technology did impact oxygenator durability with Gp 1 requiring seven (63.6%) oxygenator exchanges compared to zero (0.0%) in Gp 2 and two (7.4%) in Gp 1. While advancements in ECMO technology have resulted in improved oxygenator durability, outcomes in patients requiring such support for PCS continue to be poor.
- 28 February 2012
- Published by Hindawi Limited in Journal of Cardiac Surgery
- Vol. 27 (2) , 246-252
Have Changes in ECMO Technology Impacted Outcomes in Adult Patients Developing Postcardiotomy Cardiogenic Shock?
Extracorporeal membrane oxygenation (ECMO) technology has undergone several advancements over the last decade. We sought to compare current ECMO technology to older ones to determine how these technological improvements have impacted outcomes in patients suffering from postcardiotomy cardiogenic shock (PCS). Between 2005 and 2010, 49 patients received ECMO as support for PCS following elective cardiac surgery. Patients were divided into three groups. Group 1 (Gp 1, n = 11) patients received a Biomedicus pump with an Affinity oxygenator, Group 2 (Gp 2, n = 11) patients received a Biomedicus pump with a Quadrox D oxygenator, and Group 3 (Gp 3, n = 27) patients received a Rotaflow pump with a Quadrox D oxygenator. Groups were compared with regards to adverse events and ability to wean. Adverse event analysis showed no statistically significant difference between groups in incidence of stroke (p = 0.08), renal failure (p = 0.88), or bleeding requiring reexploration (p = 0.10). Changes in technology did little to improve weaning rates from ECMO (Gp 1 = 63.6%, Gp 2 = 45.5%, and Gp 3 = 55.6%). Similar trends were detected in hospital survival (Gp 1 = 27.3%, Gp 2 = 27.3%, and Gp 3 = 33.3%). Technology did impact oxygenator durability with Gp 1 requiring seven (63.6%) oxygenator exchanges compared to zero (0.0%) in Gp 2 and two (7.4%) in Gp 1. While advancements in ECMO technology have resulted in improved oxygenator durability, outcomes in patients requiring such support for PCS continue to be poor.
- 22 June 2010
- Published by Elsevier in Transplantation Proceedings
- Vol. 42 (5) , 1784-1787
The Effect of Recipient Hepatitis C Virus Infection on Outcomes Following Heart Transplantation
- 22 June 2010
- Published by Elsevier in Transplantation Proceedings
- Vol. 42 (5) , 1784-1787
The Effect of Recipient Hepatitis C Virus Infection on Outcomes Following Heart Transplantation
- 15 April 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 89 (7) , 873-878
Impact of Donor High-Risk Social Behaviors on Recipient Survival in Cardiac Transplantation
Objective. To investigate the impact of cardiac donor participation in high-risk social behaviors (HRSBs) on recipient survival. Methods. Retrospective chart review queried cardiac transplantations performed at our institution from August 1994 to November 2007 involving donors known to have engaged in HRSBs. Kaplan-Meier methodology was used to analyze survival rates, and a Cox proportional hazards regression was performed to determine the impact of donor HRSBs on survival. Results. We identified 143 donors with social histories containing the following HRSBs: incarceration (n=69), unprofessional tattoos or piercings (n=44), alternative lifestyle practice (n=11), cocaine use (n=60), heroin smoking (n=6), marijuana use (n=79), oral narcotic abuse (n=20), and intravenous drug use (n=21). At the time of donation, viral screens detected 10 donors who were hepatitis B virus (HBV) positive, 11 donors who were hepatitis C virus (HCV) positive, and no donors who were positive for the HIV. One-year and 5-year survival were 92.2% and 84.4%, respectively. Cox regression analysis found only donor HCV infection to be associated with poorer recipient survival (P=0.14). Conclusion. Using cardiac allografts from high-risk donors who are serologically negative for viruses does not seem to impact recipient survival. There is a considerable risk for transmission of HBV and HCV when these are detected by pretransplant screens. However, if pretransplant screening does not discover donor HBV, HCV, or HIV infection, it is unlikely that subclinical disease transmission will occur.
- 15 April 2010
- Published by Wolters Kluwer Health in Transplantation
- Vol. 89 (7) , 873-878
Impact of Donor High-Risk Social Behaviors on Recipient Survival in Cardiac Transplantation
Objective. To investigate the impact of cardiac donor participation in high-risk social behaviors (HRSBs) on recipient survival. Methods. Retrospective chart review queried cardiac transplantations performed at our institution from August 1994 to November 2007 involving donors known to have engaged in HRSBs. Kaplan-Meier methodology was used to analyze survival rates, and a Cox proportional hazards regression was performed to determine the impact of donor HRSBs on survival. Results. We identified 143 donors with social histories containing the following HRSBs: incarceration (n=69), unprofessional tattoos or piercings (n=44), alternative lifestyle practice (n=11), cocaine use (n=60), heroin smoking (n=6), marijuana use (n=79), oral narcotic abuse (n=20), and intravenous drug use (n=21). At the time of donation, viral screens detected 10 donors who were hepatitis B virus (HBV) positive, 11 donors who were hepatitis C virus (HCV) positive, and no donors who were positive for the HIV. One-year and 5-year survival were 92.2% and 84.4%, respectively. Cox regression analysis found only donor HCV infection to be associated with poorer recipient survival (P=0.14). Conclusion. Using cardiac allografts from high-risk donors who are serologically negative for viruses does not seem to impact recipient survival. There is a considerable risk for transmission of HBV and HCV when these are detected by pretransplant screens. However, if pretransplant screening does not discover donor HBV, HCV, or HIV infection, it is unlikely that subclinical disease transmission will occur.
- 1 April 2008
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (4) , 357-361
Decay-accelerating Factor Expression May Provide Immunoprotection Against Antibody-mediated Cardiac Allograft Rejection
- 1 April 2008
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 27 (4) , 357-361
Decay-accelerating Factor Expression May Provide Immunoprotection Against Antibody-mediated Cardiac Allograft Rejection